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Abstract
The recent development of gene editing tools and methodology for use in livestock enables the production of
new animal disease models. These tools facilitate site-specific mutation of the genome, allowing animals carrying
known human disease mutations to be produced. In this review, we describe the various gene editing tools and
how they can be used for a range of large animal models of diseases. This genomic technology is in its infancy
but the expectation is that through the use of gene editing tools we will see a dramatic increase in animal model
resources available for both the study of human disease and the translation of this knowledge into the clinic.
Comparative pathology will be central to the productive use of these animal models and the successful translation
of new therapeutic strategies.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Large animal models of disease
As the world population expands in number and
increases in wealth, with people living longer than
before, demands on the medical community to increase
its arsenal of disease treatments are relentless. Although
much debated, animal studies remain central to many
regulatory systems as a safety checkpoint for testing
new treatments – whether based on drugs, genetic solu-
tions, or regenerative processes [1–4]. Additionally,
prior to this late step in the development of a new treat-
ment, research studies in animals often play a crucial
role in providing both understanding of the disease and
associated pathology, and identifying the target event
in the disease to which the treatment is directed. By far
the most utilized mammal in both of these phases is the
laboratory mouse, and it is without question that studies
in mice have dramatically accelerated our ability to
treat disease. Nevertheless, as highlighted in numerous
other reviews in this issue of The Journal of Pathology,
mouse data can be inadequate in its ability to translate
scientific progress from ‘bench to bedside’.
Significant differences between mouse and man,
including physical size, limit the mouse as a model of
human disease. An often cited example is that of cystic
fibrosis, where mice carrying mutations of relevance
to humans do not show the full panoply of symptoms
associated with human cystic fibrosis [5–8]; the same is
true for other diseases such as Lesch–Nylan syndrome
[9] and Huntington’s disease [10,11]. As a result, focus
is increasingly directed to larger animals, with dogs and
pigs seeing greatest use [12] in addition to primates [13].
For many years, medical advances have been restricted
by the availability of appropriate model species carrying
disease conferring mutations. This small repertoire of
naturally occurring diseases has been augmented by
transgenic approaches, and good models have emerged,
for example the GIPR (dn) [14] and INSC94Y [15]
diabetic pigs. The considerable progress achieved since
the first engineered large animal model of human dis-
ease was reported [16] has been reviewed [17–19].
A recently developed set of tools, commonly termed
gene editors (reviewed in refs 20–22), now allow those
who want to understand disease processes or develop
novel treatments to choose the most appropriate animal
species for their studies.
Gene editing with designer nuclease editors
Gene editors are site-specific nucleases that introduce
double-strand breaks (DSBs) at specific loci within the
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genome. The engineered DSBs trigger DNA repair by
two competing pathways, non-homologous end join-
ing (NHEJ) or homology-directed repair (HDR), which
facilitate the generation of knockout and knock-in ani-
mals, respectively. Currently, there are four groups of
gene editors available. The first are the meganucle-
ases, which remain unpopular due to difficulties in pro-
duction and limitations in target site selection [23].
The other three groups – zinc finger nucleases, tran-
scription activator-like effector nucleases, and clustered
regularly interspaced palindromic repeats (CRISPR)
and CRISPR associated 9 (Cas9) nuclease – are seeing
rapidly increasing use in animals.
Zinc finger nuclease (ZFN)
ZFNs are adapted from the eukaryotic zinc finger
class of transcription factors and utilize Cys2-His2
DNA-binding motifs for target recognition [24]. The
zinc finger (ZF) is one of the most common DNA
binding motifs in mammals [25], with a single finger
interacting specifically with a triplet of nucleotides.
ZFNs are assembled by combining three to four zinc
fingers in tandem, recognizing 9–12 base pairs of
sequence, respectively, and tethering one half of the
catalytic domain of the obligate dimeric endonuclease
FokI [24]. Thus, ZFNs are used in pairs that bind
sequences on opposite DNA strands to facilitate dimer-
ization of FokI to catalyse a DSB in the target DNA.
This requirement for targeting two opposite strands in
close proximity, as well as the use of heterodimeric
FokI endonucleases, offers an advantage towards
increasing site specificity and mitigating off-target
concerns [24,26]. The design of ZFNs is constrained
by a requirement for high GC content, recognition of
triplets, and an obligate requirement for a short spacer
sequence. These requirements make rational design and
assembly of ZFNs a somewhat daunting task for most
laboratories [27]. Additional bottlenecks include the
unpredictability of ZFN efficiency, requiring intensive
pre-screening of several ZFNs and targeting sites [28].
The oligomerized pool engineering strategy [29,30] and
context-dependent assembly (CoDA) [31] have been
developed to overcome these deficiencies. In large ani-
mals, including pigs, ZFNs have been used successfully
for editing the genome.
Transcription activator-like effector nuclease
(TALEN)
Similar to ZFNs, transcription activator-like (TAL)-
effector modules are found naturally, being used by
Xanthomonas bacteria to specifically bind host DNA
and modify metabolism in favour of bacterial prop-
agation [32]. However, unlike zinc fingers that bind
three nucleotides, each TAL module binds to a sin-
gle nucleotide. TAL modules consist of 34 amino acids
with residues at positions 12 and 13 (repeat variable
diresidue; RVD) conferring DNA recognition. Based on
the target sequence, it is possible to choose appropriate
RVDs, assemble a modular array, and fuse to FokI to
generate a TALEN [33–38]. As with ZFNs, TALENs
are utilized as pairs with FokI dimerization in a spacer
region. The relative ease of TALEN design and assem-
bly has been illustrated by a recent publication in which
a library of TALENs was assembled to target 18 700
human protein coding genes [39]. For the same reasons,
TALENS have been utilized to edit porcine, sheep, and
cattle genomes [21,40–42]. Similar to ZFNs, off-target
cleavage remains a concern, which is mitigated by the
use of obligate heterodimer FokI nucleases [43].
Clustered regularly interspaced palindromic repeats
(CRISPR) and CRISPR associated 9 (Cas9) nuclease
The CRISPR/Cas9 system evolved in archaea and
eubacteria as an RNA-based adaptive immune system to
detect and cleave invading viruses and plasmids [44,45].
Currently, the most commonly used CRISPR/Cas9 sys-
tem is a modified version of that used by Streptococcus
pyogenes and consists of a guide RNA and Cas9 endonu-
clease. These two components form a complex, with a
20-nt section of the guide sequence determining target
identity via Watson–Crick base pairing, followed by
cleavage by Cas9 to create a DSB. In a recent landmark
publication, five genes were simultaneously targeted by
the CRISPR/Cas9 system [46] in a mouse model.
The relative ease of design and manipulation, due to
the requirement for a single as opposed to two recogni-
tion sites, makes the CRISPR/Cas9 system awidely used
and desirable editor. However, off-target cutting remains
amajor concern for this system [47]. In this regard, mod-
ifications of Cas9 nuclease are critical for overcoming
off-target concerns. Single-strand nickase activity [48],
Cas9–FokI fusion nucleases [49], and split dimerizable
Cas9 [50] offer the potential to reduce the off-target con-
cerns of the CRISPR/Cas9 system. Taken together, the
CRISPR/Cas9 system has proven to be an easy, versatile
system, and currently the most widely used gene editor.
Gene editors engineer genetic variation
Following editor activity, DSB repair is carried out
by one of two main pathways (see Figure 1). Non-
homologous end joining or NHEJ (a relatively broad
term comprising of canonical- and alternative NHEJ
pathways mediated by DNA ligase IV and I/III, respec-
tively) is the major repair pathway that is active in all
phases of the cell cycle. Canonical NHEJ (c-NHEJ)
is the predominant pathway following Cas9-mediated
DSB in the murine genome, with experimental efficien-
cies reaching 20–60% [40,51,52]. In brief, following
DSB (Figure 1A), Ku proteins bind the cut ends; the
Ku:DNA complex serves as a platform for other com-
ponents of the NHEJ repair pathway such as nuclease,
polymerase, and DNA ligase IV to dock and initiate
repair (Figure 1B). DNA ligase IV has limited sequence
preference and can ligate DNA strands across gaps, lig-
ate incompatible ends, and even ligate single strands.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 247–256
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This mechanistic flexibility of DNA ligase IV in the
NHEJ pathway results in a significant variability of pro-
cessed ends resulting in insertions or deletions (indels)
around cut sites. When such indels are introduced into
the open reading frame of a functional gene, the result
can be a frameshift and functional knockout of the
gene. As NHEJ is both error-prone and the predominant
repair pathway following DSB, frequently no additional
manipulation of the cell is required for ablation of target
gene function besides introduction of editors.
When functional knockout is not the desired goal,
more precise modifications of the genome including
introduction of point mutations, modification of codons,
introduction of reporters or replacement of alleles can be
performed. Such precise modifications are dependent on
HDR (Figure 1B). The frequency of HDR inmammalian
systems is extremely low, but can be improved by sev-
eral orders of magnitude with the introduction of a DSB
at the target site [53]. Following a DSB, repair by HDR
is dependent on the occurrence of 5’-end resection and
the generation of single-stranded 3’ ends [54,55]. The
single-stranded 3’ ends serve as a scaffold for assembly
of Rad51 filaments instead of Ku proteins for initiating
repair. The Rad51 element directs strand invasion of a
homologous DNA template, while the 3’ end serves as a
primer for repair synthesis [56]. It should be noted that
even with Cas9-induced DSBs, the efficiency of HDR
is only 0.5–20% in mouse systems [40,51,57] because
such repair takes place within the context of a compet-
ing NHEJ pathway. By contrast to NHEJ that takes place
throughout the cell cycle [58], HDR is only functional
in the S and G2 phases [48,51,52]. Binding of Ku pro-
teins to exposed ends prevents end resection and biases
the pathway to NHEJ; suppression of Ku proteins has
been shown to significantly improve the rate of HDR
in gene editing experiments [30,59]. Likewise, inhibi-
tion of ligase IV by the synthetic inhibitor SCR7 results
in up to a 19-fold increase in the rate of Cas9-mediated
HDR in mammalian cell lines [59]. Encouragingly, the
use of SCR7 in the context of porcine cells and embryos
has been in line with the findings from mice, and it
is expected that SCR7 will find greater applicability
in HDR experiments in porcine systems (Telugu et al,
unpublished results).
Contrary to DSBs, single-strand breaks and gaps are
preferentially repaired by the HDR pathway. Using
D10A Cas9 nickase, a targeted nick or gap will, in the
next round of DNA synthesis, become a DSB and ini-
tiate repair by HDR in mammalian cells. Additional
evidence for this in mammalian systems comes from
the use of site-specific nickases, such as meganucleases
[60], zinc finger nucleases [61–63], and CRISPR/Cas9
[45,48]. For the purposes of gene editing, the use of nick-
ases that generate a single-strand nick has the advantage
that nicks are not repaired by c-NHEJ. However, the
induction of HDR from nicks is usually much less effi-
cient than that from DSBs. In this context, HDR is still
expected to be advanced by the use of DSB and inhibi-
tion of the c-NHEJ pathway.
Engineering large animals: SCNT versus zygote
injections
The majority of genetically engineered livestock are
pigs and in this species, somatic cell nuclear transfer
(SCNT) or cloning remains by far the most popular pro-
duction method (see Figure 2). The technique involves
the generation of somatic cells (typically porcine fetal
fibroblasts) carrying the intended genetic modification
and using these cells as donors in cloning experiments
(Figure 2B). For cloning, the metaphase II plate within
the oocyte comprising the genetic material is removed,
and the genetically modified cell fused with the enucle-
ated oocyte to restart embryo development. Reconsti-
tuted oocytes are typically transferred into the oviducts
of recipient animals. Editor technology can be easily
applied to create either NHEJ- or HDR-driven muta-
tions within the donor cell in vitro (Figures 2A and
2B). Usually a pre-screening or selection strategy is
used to enable enrichment for cells carrying the desired
mutation.
The major advantage of SCNT over direct embryo
injection with editor reagents is the predictable geno-
type of piglets and the ability to generate clonal lines
of edited animals. However, SCNT suffers from serious
disadvantages, such as the relatively low viability of
reconstituted embryos and, consequently, pregnancy
losses following embryo transfer. Therefore, a high
number of reconstituted embryos, normally in the range
of 100–150 embryos, are typically transferred into
recipient animals to establish pregnancies. Difficulty in
maintaining primary somatic cells in culture for a suffi-
cient period to allow pre-screening and expansion prior
to performing SCNT constitutes an additional draw-
back. Moreover, offspring derived from SCNT often
have developmental defects, which preclude analysis of
the intended phenotype in the first generation. Finally,
SCNT is technically challenging and resource-intensive,
and therefore remains unavailable to all but specialized
laboratories. Even in established labs, the outcome of
SCNT is unpredictable. However, efficiencies of SCNT
are steadily rising owing to improvements in culture
regimes [64] and SCNT remains a major driver for
generating gene-edited and other genetically engineered
livestock, especially pigs.
An alternative to SCNT is performing gene editing
directly in embryos. The cocktail of editors and targeting
vectors (for HDR) can be microinjected into the cyto-
plasm or pronucleus of zygotes (Figures 2A and 2B).
In pigs, the pronucleus is not readily visible, and there-
fore cytoplasmic injections remain the preferred route
for generating edited animals. The procedure is surpris-
ingly simple. Embryos at early stages can be recovered
by surgical flush from the oviduct of donor embryos. The
mRNA for editors can be injected into the cytoplasm of
one-cell zygotes (Figure 2B), which are then transferred
into the oviducts of synchronized recipients to generate
edited pigs [65], sheep, and cattle [42].
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 247–256
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Figure 1. Site-specific nuclease (SSN)-mediated gene targeting. (A) Double-stranded breaks (DSBs) at the target site can be induced by
two classes of SSNs: either nucleases fused to a DNA-binding domain, eg ZFN and TALENs (left), or an RNA-guided nuclease (CRISPR/Cas9;
right). (B) KU80 proteins bind the resected ends to initiate an error-prone non-homologous end joining (NHEJ) pathway, resulting in the
potential introduction of insertions or deletions of a few nucleotides at the cut site (indels) and the generation of a premature stop codon
effectively knocking out the allele. (C) Conversely, the DNA strands can undergo repair by homology-directed repair (HDR). In this case, the
DNA at the cut site undergoes end resection; binds to Rad51 proteins, initiating strand invasion of the repair template (either a single- or
a double-stranded DNA repair template); and allows high fidelity repair and precise editing, and replacement of alleles.
There are a few limitations in performing embryo
injections: embryonic losses due to the toxicity of edi-
tors; incidence of mosaicism of edits; unpredictability
of the percentage of edited animals; and the number of
different genotypes produced. For example, as noted by
Lillico et al [65], a wide distribution of genome edits
is identified in the progeny of zygote injections. A sig-
nificant number of offspring from embryo editing pro-
cedures by TALENs and ZFNs have been found to be
wild type, with some edited animals carrying mutations
that are in-frame and few individual animals carrying
more than one mutation (mosaic), thereby confound-
ing the investigation of phenotype in the first generation
[65]. Refinements to these methods are being devised.
In a more recent experiment, all 18 piglets generated by
CRISPR injections across three pregnancies were found
to be edited (Telugu et al, unpublished results). Given
these findings, the lack of edited progeny is less of a
concern; however, in-frame mutations and mosaic geno-
types remain a limitation. The field excitingly awaits
success with oligo-based HDR, which offers consider-
able control over the resulting genotype.
New large animal models of disease
Gene editors now allow the precise engineering of ani-
mal disease models. If a mutation can occur in nature, it
can be copied by use of the gene editors. Thus, mutations
in the human genome known to be causative or associ-
ated with a human pathology can be replicated in the
genome of an animal. Gene editing technology in large
animals has only been made possible over the last few
years and to date, only a few studies have been initiated
(Table 1). We anticipate this to change dramatically over
the next few years. To illustrate the potential, we have
listed the range of genetic mutations possible, giving
examples of disease models that could be engineered.
Frame shift mutation
Conceptually, the simplest mutation would result from
a NHEJ event at a target genetic locus. In most cases,
the target would be within the coding region of a gene
and this would result in a frame-shift event with regard
to the gene’s open reading frame. The likely outcome
would be to bring a premature stop codon into frame
and produce a truncated protein. This is exactly what
has been achieved for the porcine RELA gene in a
project addressing resilience to viral disease [65]. In this
case, the final exon of the gene was targeted, with the
prediction being that the truncated RELA protein would
retain some function; alternatively, targeting NHEJ to
an earlier exon often leads to nonsense-mediated decay
of the transcript and hence functional knockout of the
protein [66].
An example disease where this strategy could be
applied is Crohn’s disease. A frameshift mutation
(3020insC) in NOD2 thought to reduce the NFκB-
induced innate immune response in these patients is
associated with susceptibility to Crohn’s disease [67].
Through gene editors, this frameshift could be easily
produced in an animal model. Given the association
of this frameshift mutation in a number of diseases,
from cancer [68] to sepsis [69], and associated with
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 238: 247–256
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Figure 2. Legend on next page.
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treatment regime prognosis [70], such an engineered
animal model could have wide-ranging utility.
Allele swap
Amore elegant mutation strategy involving HDR would
be to engineer an allele swap. In this scenario, a disease
associate allelic variant would be produced. This has
already been achieved for cystic fibrosis (CF) using
‘old’ transgenic methodology, with the resulting animals
demonstrating research and translational opportunities.
The most common CF-associated mutation is CFTR
ΔF508; however, when this mutation was engineered
into mice [71], they failed to replicate the CF pathology;
when the same mutation was engineered into pigs, a
range of CF pathology was observed [72–74]. It is now
timely to produce large animal models carrying other
CF-associated alleles. Although engineered CF pigs are
available, some believe that sheep may represent an
alternative model species [75], and sheep are currently
central to the development of gene therapy strategies to
mitigate this disease [76,77]. Although some differences
in lung anatomy and biochemistry manifest for these
species in comparison to humans [78,79], the inability
of rodent models to replicate the disease justifies the
research effort.
Engineering models provide information on the dis-
ease and offer a translational model to develop new and
effective therapies. This includes gene therapy, with CF
seen as potentially an early success story. Gene edi-
tors have been used to successfully correct and restore
function to the CFTR in human cells in vitro [80]. In
animals, we have the opportunity to engineer disease
pathology and then validate the treatment prior to human
trials.
Repeat sequence expansion
A more challenging allele swap is represented in dis-
eases caused by expansion of unstable trinucleotide
repeats [81]. Spinocerebellar ataxia type 1 is an auto-
somal dominant neurodegenerative disorder. The neu-
ropathology involves selective neuron loss from the
cerebellum and disease severity reflects expansion size
of the highly polymorphic CAG repeat [82]. A sim-
ilar situation exists for Huntington’s disease, where
expansion of a polyglutamine tract encoded within exon
1 of the huntingtin gene (HTT) results in pathology.
The opportunity for large animal models of this dis-
ease has been championed [11], with initial progress
achieved through microinjection of sheep zygotes with
an expression cassette encoding the huntingtin genewith
an expanded CAG repeat [83]. Excitingly, it is possible
that such animal models of neurodegenerative disease
can be used to develop effective treatment for different
protein misfolding diseases [84].
Exon/domain deletion
The differences between the different gene editors direct
their application. For instance, the use of CRISPR/Cas9
with two guide RNAs allows the efficient deletion of
DNA sequence between the two guides, even over rel-
atively large genomic distances [85]. Proteins often
consist of several peptide domains, each of which
is often encoded by a single exon within the gene,
and sequence deletion can be associated with some
human diseases; deletion of exon 9 of the presenilin
1 gene (PSEN1) causes some forms of Alzheimer’s
disease [86]. Although a number of mouse models of
Alzheimer’s disease exist [86–92], treatments devel-
oped in these rodent models have had very limited
impact in the clinic [93], presumably linked to the large
differences in brain architecture between humans and
these rodents. Large animal models should be able to
contribute to the pressing need for better translation
strategies.
Chromosomal translocation
Chromosomal translocations are severe genome rear-
rangements and those that are not lethal are often
associated with pathology. Examples include Burkitt’s
lymphoma [94] and acute myeloid leukaemia [95], for
which successful treatment is an ongoing challenge
[96]. Although conceptually similar in strategy, chro-
mosomal translocations present a bigger challenge
for gene editor technology than sequence deletion.
Translocation has been achieved in cells [97] in vitro
but remains to be demonstrated in animals.
Monkeys and primates
Although all human disease deserves research attention,
it is for neural disorders that we predominantly jus-
tify the use of non-human primates [13]. Gene editors
can and have been used in monkeys [98], for example
CRISPR/Cas9 disruption of the dystrophin gene (DMD)
in the rhesus macaque [99]. We can anticipate more
research activity to rapidly emerge.
In the illustrative examples above, the desire is to
engineer into the genome a disease mutation. This will
Figure 2. Genome editing in pigs. (A) For gene targeting without editors, a double-stranded DNA targeting vector with the intended gene
modification (purple square) with a selectable marker, eg a neomycin resistance cassette, is used and the cells that survive the selection
are used for gene targeting. (B) For targeting with editors, a selection of tools such as zinc finger nucleases (ZFNs), TAL-effector nucleases
(TALENs), and clustered regularly interspaced palindromic repeats (CRISPR)–CRISPR associated 9 (Cas9) nuclease can be used to introduce
double-strand breaks in the genome. When used by themselves, the editors will generate knockout of genes. In combination with either a
single-stranded or a double-stranded DNA as the repair template, the editors will facilitate gene targeting. The editors, with or without the
targeting vectors, can be electroporated into somatic cells and used as donors for nuclear transfer or cloning to generate edited animals
(Option-I), or microinjected into the cytoplasm of embryos (Option-II). (C) A comparison of conventional gene targeting and genome editing
with editors is shown.
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Table 1. Gene-edited (mini-)pigs addressing human disease
Gene(s) Editor Route Reference
NHEJ
PPARγ ZFN SCNT [121]
α 1,3GT ZFN SCNT [107]
LDLR TALEN SCNT [39]
α 1,3GT ZFN SCNT [113]
CMAH ZFN SCNT [110]
IL2RG ZFN SCNT [118]
α 1,3GT CMAH ZFN SCNT [114]
α 1,3GT TALEN SCNT [120]
α 1,3GT ZFN SCNT [106]
RAG1 TALEN SCNT [109]
RAG2 TALEN SCNT [109]
RAG2 TALEN SCNT [111]
DJ-1 TALEN SCNT [122]
SLA-1, 2, 3 CRISPR/Cas9 SCNT [115]
CD1d CRISPR/Cas9 SCNT [119]
CD1d CRISPR/Cas9 CPI [119]
TYR CRISPR/Cas9 SCNT [123]
PARK2, PINK1 CRISPR/Cas9 SCNT [123]
IgM CRISPR/Cas9 SCNT [124]
PKD1 ZFN SCNT [108]
α 1,3GT , CMAH, iGb3S CRISPR/Cas9 SCNT [112]
Npc1l1 CRISPR/Cas9 CPI [117]
HDR
CMAH ZFN SCNT [110]
APC TALEN SCNT [116]
require the design and production of gene editors, usu-
ally in conjunction with a DNA template carrying the
desired mutation, targeting a precise, predetermined
genetic locus. This approach and resources would pro-
vide valuable information for the opposite goal, that
of correcting a deleterious mutation. Such corrective
strategies, whilst unlikely to be applied to livestock in
agriculture, could have utility for some domesticated
pet species and play to the international discussion on
whether gene editors should be used on the human
germline [100–103].
The next 5 years
The continuously increasing need for new disease treat-
mentsmust be juxtaposed against the current disappoint-
ing rate of new drugs developing through to clinical use.
There are many reasons for the high attrition rate during
drug discovery [104], with the paucity of reliable ani-
mal models being only one. However, utility and ease
of use indicate that gene editing technology will have
a role in meeting this need, overcoming the historically
technical and laborious challenges of transgenesis [105],
thus providing a strategy to broaden the repertoire of
useful animal disease models significantly beyond that
currently available. Because of the ability to make many
disease models, this technology should go on to affect
more than the highest profile diseases that often attract
the attention of funding agencies.
We now face a research environment where the most
appropriate animal species can be utilized to bridge
the ‘bench to bedside’ development gap. For some dis-
eases this may be laboratory animals but for others it
will be livestock. The choice of species will depend on
both comparative biology and economic factors. In addi-
tion to the use of mini-pigs continuing, we anticipate
expanding interest in standard pigs as well as sheep,
and the expansion of studies using genome-engineered
primates. Indeed, there is no technical reason why
gene-editing tools could not be applied to any species
for which sufficient embryology expertise exists.
The ability to engineer the same disease mutation into
several species and then compare the different models
against the observed human pathology is a powerful
strategy to advance new treatments. It will, however,
require the appropriate handling and analysis facilities
for a range of differently sized animal species plus
the scientific skill base to perform these comparative
studies – and central to this will be pathology.
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